Saakshi Medtech and Panels Limited — PPTs, 01-07-2025: Investor Presentation

1. Financial Highlights:

Revenue remained steady with half-yearly figures around Rs. 48–61 Cr. The company invested Rs. 46 Cr in CAPEX to support growth and modernize facilities. Interest costs have been reduced, improving financial efficiency. Deferred and prototype orders impacted PAT marginally. The near completion of a new 41,000 sq. ft. facility is expected to reduce rental expenses by Rs. 2 Cr annually, enhancing margins going forward.

2. Strategic Initiatives & Growth Drivers:

Significant ramp-up in the EV electrical control panels business, with first-quarter sales surpassing the entire previous year. The company expanded its product portfolio with a fully operational radiator line. A new wind turbine manufacturing facility is under setup, expected operational by Sept 2025. Post-CAPEX phase, emphasis will be on asset utilization and ROI, along with operational cost discipline and streamlined workforce.

3. Business Developments:

Commercial production commenced at Factory Unit III in Pimpri Chinchwad, Pune. The company secured manufacturing licenses for medical devices and diagnostic X-ray equipment. It expanded testing laboratory capabilities with NABL accreditation and received recognition for zero-defect quality standards. Internal restructuring in the wind turbine vertical led to order deferments but aims to strengthen that segment.

4. Market Position & Competitive Advantage:

SAAKSHI leverages diversified verticals—electrical panels, fabrication, medical devices—enabling scale and product synergy. Its established leadership in EV panel supplies and medical device manufacturing, combined with ongoing capacity expansion, strengthens competitive positioning and prepares it for high-growth market segments.

5. Investor Implications:

Robust CAPEX investments and strong EV segment growth signal positive growth potential. Cost control and facility expansion enhance margin profiles. Execution risk exists in wind turbine and defense verticals due to order delays and restructuring but is being proactively addressed. Investors should monitor asset utilization and timely ramp-up of new capacities for sustainable performance gains.